Target intelligence / Profile preview

G2/mitotic-specific cyclin-B1 (CCNB1)

Target
CCNB1
Molecular classification
Other, Protein kinase regulator, Cell cycle regulator
01

Overview

G2/mitotic-specific cyclin-B1 (CCNB1) is a key regulatory protein essential for the control of the cell cycle at the G2/M transition. It complexes with cyclin-dependent kinase 1 (CDK1) to form the maturation-promoting factor (MPF), which drives the cell from the G2 phase into mitosis. CCNB1 expression is tightly regulated, peaking during the G2/M phase and rapidly degrading as cells exit mitosis. In many cancers, including breast, lung, and colorectal cancers, CCNB1 is constitutively overexpressed, promoting uncontrolled cell proliferation and tumor progression. Consequently, CCNB1 is a highly attractive therapeutic target in oncology. Therapeutic strategies include small-molecule inhibitors of the CDK1/CCNB1 complex (such as CID-078, dinaciclib, and RO-3306), natural products that downregulate its expression (such as resveratrol), and peptide-based cancer vaccines designed to elicit an immune response against CCNB1-overexpressing tumor cells.

Other names
Cyclin B1CCNB1CCNBG2/mitotic-specific cyclin-BG2/mitotic-specific cyclin-B1Ccnb1
02

Mechanism of action

Inhibition of the CDK1/Cyclin B1 complex, downregulation of CCNB1 expression, or active immunotherapy targeting CCNB1-expressing tumor cells

03

Biological functions

Cell cycleCell divisionMitosisCell proliferationApoptosis
04

Disease associations

Cancer
05

Safety considerations

MyelosuppressionGastrointestinal toxicityMitotic catastrophePotential for autoimmune reactionsOff-target toxicity in normal proliferating tissues
06

Interacting drugs

7 more in the full profile.

07

Biomarkers

CCNB1 expression levelp53 statusE2F transcription factor activityCyclin B1-specific CD8+ T cell response

Beyond the preview

Go deeper on G2/mitotic-specific cyclin-B1 (CCNB1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on G2/mitotic-specific cyclin-B1 (CCNB1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call